388 related articles for article (PubMed ID: 12740924)
1. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
2. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
3. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells.
Abdullah N; Greenman J; Pimenidou A; Topping KP; Monson JR
Cancer Immunol Immunother; 1999 Dec; 48(9):517-24. PubMed ID: 10602889
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of autologous blood mononuclear cells used for auto-infusion together with monoclonal antibodies in tumor treatment.
Frödin JE; Pihlstedt P; Lefvert AK; Mellstedt H
Hybridoma; 1987 Dec; 6(6):555-64. PubMed ID: 3325401
[TBL] [Abstract][Full Text] [Related]
5. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
Masucci G; Wersäll P; Nielsen J; Nielsen HK; Wigzell H; Mellstedt H
Hybridoma; 1989 Oct; 8(5):507-16. PubMed ID: 2807310
[TBL] [Abstract][Full Text] [Related]
7. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
8. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
9. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
10. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines.
Lieberman MD; Sigal RK; Williams NN; Daly JM
J Surg Res; 1991 Apr; 50(4):410-5. PubMed ID: 1673486
[TBL] [Abstract][Full Text] [Related]
14. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
[TBL] [Abstract][Full Text] [Related]
15. Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.
Tsitsilonis OE; Tsavaris NB; Kosmas C; Gouveris P; Papalambros E
J Chemother; 2003 Aug; 15(4):387-93. PubMed ID: 12962368
[TBL] [Abstract][Full Text] [Related]
16. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
Blottière HM; Steplewski Z; Herlyn D; Douillard JY
Hum Antibodies Hybridomas; 1991 Jan; 2(1):16-25. PubMed ID: 1908336
[TBL] [Abstract][Full Text] [Related]
17. Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).
Masucci G; Lindemalm C; Frödin JE; Hagström B; Mellstedt H
Hybridoma; 1988 Oct; 7(5):429-40. PubMed ID: 3198133
[TBL] [Abstract][Full Text] [Related]
18. The monoclonal antibody CJA3 down-regulates the susceptibility of human tumor cell lines to natural cell-mediated cytotoxicity.
Allen JI; Ferrone S; Boue D; Kay NE
J Immunol; 1986 Mar; 136(6):2318-22. PubMed ID: 3950415
[TBL] [Abstract][Full Text] [Related]
19. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
20. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]